Protection of clinical trial subjects in countries outside the EU
Posted in category:
Publication
Published on:
In this briefing paper, Wemos and SOMO call upon the European Parliament, the European Commission and the European Medicines Agency to take measures at the following three levels: 1) Vigorously pursue the integration of ethical principles into EMA procedures, 2) Increase transparency in clinical trials outside the EU and 3) Strengthen capacity in low and middle income countries.
Do you need more information?
-
Irene Schipper
Senior Researcher
Partners
Publication
Related news
-
EU health data law rolls out the red carpet for Big TechPosted in category:Long read
Irene SchipperPublished on: -
Civil society coalition urges EU to put the interests of patients and citizens at the heart of the European Health Data SpacePosted in category:Published on:Statement
-
